TherapeuticsMD (NASDAQ:TXMD) Research Coverage Started at StockNews.com

Research analysts at StockNews.com assumed coverage on shares of TherapeuticsMD (NASDAQ:TXMD) in a report issued on Sunday. The firm set a “hold” rating on the stock.

TherapeuticsMD Stock Performance

Shares of TXMD stock opened at $1.61 on Friday. TherapeuticsMD has a fifty-two week low of $1.61 and a fifty-two week high of $4.35. The stock’s 50-day simple moving average is $2.00 and its 200-day simple moving average is $2.18.

TherapeuticsMD (NASDAQ:TXMD) last issued its quarterly earnings results on Friday, May 10th. The company reported ($0.07) earnings per share for the quarter. The firm had revenue of $0.31 million during the quarter.

Institutional Investors Weigh In On TherapeuticsMD

A hedge fund recently bought a new stake in TherapeuticsMD stock. Prosperity Consulting Group LLC bought a new stake in TherapeuticsMD, Inc. (NASDAQ:TXMD) during the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor bought 24,500 shares of the company’s stock, valued at approximately $56,000. Prosperity Consulting Group LLC owned about 0.21% of TherapeuticsMD as of its most recent SEC filing. 30.74% of the stock is currently owned by institutional investors.

About TherapeuticsMD

TherapeuticsMD, Inc operates as a pharmaceutical royalty company in the United States. It has a license agreement with Mayne Pharma to commercialize the IMVEXXY, BIJUVA, and ANNOVERA prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brand names. The company sells its prescription pharmaceutical products and prenatal vitamin products through wholesale distributors and retail pharmacy distributors.